MedPath

Effects of Xal-Ease on Patient Compliance With Xalatan

Not Applicable
Conditions
Glaucoma
Registration Number
NCT00573638
Lead Sponsor
Augusta University
Brief Summary

The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • 40 to 80 years old
  • Diagnosis warranting treatment with Xalatan eye drops.
  • ambulatory and well functioning
Exclusion Criteria
  • non-ambulatory
  • less than 40 or greater than 80 years old
  • Not using Xalatan eye drops

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment.six months
Secondary Outcome Measures
NameTimeMethod
To determine if any of the other factors mentioned in the survey affect compliance to their medical regimensix months
To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye.6 months

Trial Locations

Locations (1)

Medical College of Georgia Health Inc

🇺🇸

Augusta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath